Risk factor
Negligible price volatility
Profitability factor
Slightly undervalued vs peers
About
Kissei Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products primarily in Japan. It offers Urief and Urief OD tablets for the treatment of dysuria; Glufast, Glubes, and Marizev tablets for type 2 diabetes; Darbepoetin Alfa BS and Epoetin Alfa BS injections for the treatment of renal anemia; Beova tablets...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITD.
Target Price
The average target price of 4547.T is 4689 and suggests 1% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Buy
Sell